Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001TM

xB 3 -001 demonstrated lymphatic system penetration and more selective tissue distribution with xB 3 -001 than trastuzumab alone. The Company has filed patent applications based on these observations and those data may have broader applicability.

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. However, FINRA regulations require all readers to sign onto our site. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

4 COMMENTS

LEAVE A REPLY